IMR Press / EJGO / Volume 39 / Issue 4 / DOI: 10.12892/ejgo4027.2018

European Journal of Gynaecological Oncology (EJGO) is published by IMR Press from Volume 40 Issue 1 (2019). Previous articles were published by another publisher on a subscription basis, and they are hosted by IMR Press on as a courtesy and upon agreement with S.O.G.

Open Access Original Research
Recurrent ovarian clear cell carcinoma: a retrospective evaluation of the efficacy and prognostic factors
Show Less
1 Department of Gynecology, Key Laboratory of Carcinogenesis and Translational Research (Ministry of Education), Peking University Cancer Hospital & Institute, Beijing, China
Eur. J. Gynaecol. Oncol. 2018, 39(4), 569–574;
Published: 10 August 2018

Purpose: The aim of this study was to investigate the effectiveness of treatment and prognostic factors in patients with recurrent ovarian clear cell carcinoma. Materials and Methods: The 78 patients with ovarian clear cell carcinoma (CCC) in Peking University Cancer Hospital from 1996 to 2015 received laparotomy and initial chemotherapy. The efficacy of surgery, chemotherapy, and prognosis of patients with recurrent CCC were evaluated. Results: The overall response rate (RR) to platinum based chemotherapy of PTX + platinum regimen showed no significant correlation with PFI in this study (p = 0.683). According to non-platinum regimen, irinotecan + mitomycin C regimen had a higher activity (RR = 41.7%) compared with topotecan regimen (RR = 20%). The overall survival (OS) had a marked correlation with tumor staging (p = 0.027), residuals (p = 0.019), second-line chemotherapy response (p = 0.003), and progression free survival (PFS, p = 0.014). Conclusions: No residual tumor in initial surgery is critical for the prognosis of patients with CCC, even in optimal cytoreductive surgery. Irinotecan, as one kind of effective chemotherapy regimen, is preferred to be conducted in patients with recurrent CCC.
Clear cell carcinoma
Second-line chemotherapy
Back to top